Teva director granted 7,242 restricted share units
Elstein Amir reported acquisition or exercise transactions in this Form 4 filing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Elstein Amir reported acquisition or exercise transactions in this Form 4 filing.
TEVA PHARMACEUTICAL INDUSTRIES LTD director Amir Elstein received a grant of 7,242 restricted share units. These units were awarded on May 28, 2026 and will vest on May 28, 2027. Each unit represents a contingent right to receive one ordinary share or, at the committee’s option, the cash value of one ordinary share.
After this grant, Elstein holds 7,242 restricted share units directly. The ordinary shares may be represented by American Depositary Shares, with each ADS currently representing one ordinary share.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Share Units | 7,242 | $0.00 | $0.00 |
Footnotes (3)
- F1. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- F2. Restricted share units were granted on May 28, 2026 and vest on May 28, 2027.
- F3. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Key Figures
Key Terms
contingent right financial
vesting financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Teva (TEVA) director Amir Elstein report in this Form 4?
AI-generated analysis. How Rhea-AI works. Not financial advice.